Naxitamab (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Naxitamab" in German language version.

refsWebsite

Global rank German rank

447^th place

751^st place

2^nd place

3^rd place

4^th place

7^th place

low place

low place

195^th place

255^th place

5,401^st place

312^th place

1seekingalpha.com

5,344^th place

low place

low place

low place

awmf.org

S1-Leitlinie Neuroblastom. AWMF-Nr.: 025/008. Abgerufen am 10. Februar 2022

doi.org

Nai-Kong V. Cheung, H. Guo, Jian Hu, D. V. Tassev, I. Y. Cheung: Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. In: OncoImmunology. Band 1, Nr. 4, 2012, S. 477–486, doi:10.4161/onci.19864, PMID 22754766.
Ketan Patel, R. J. Rossell, L. F. Pemberton, N. K. Cheung, F. S. Walsh, S. E. Moore, T. Sugimoto, J. T. Kemshead: Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2. In: British Journal of Cancer. Band 60, Nr. 6, 1989, S. 861–866, doi:10.1038/bjc.1989.380, PMID 2481486.
Jeong A. Park, Nai-Kong V. Cheung: Targets and Antibody Formats for Immunotherapy of Neuroblastoma. In: Journal of Clinical Oncology. Band 38, Nr. 16, 2020, S. 1836–1848, doi:10.1200/jco.19.01410, PMID 32167865.

fda.gov

accessdata.fda.gov

DANYELZA® (Naxitamab-gqgk) Prescribing Information. (PDF) Abgerufen am 10. Februar 2022.
Drugs@FDA: FDA-Approved Drugs. Abgerufen am 10. Februar 2022.
Drug Approval Package: DANYELZA. Abgerufen am 10. Februar 2022.
DANYELZA (naxitamab-gqgk) Approval Letter. (PDF) Abgerufen am 10. Februar 2022.

fda.gov

Drugs Trials Snapshot: Danyelza. Abgerufen am 10. Februar 2022.

mskcc.org

At Work: Physician-Scientist Nai-Kong Cheung | Memorial Sloan Kettering Cancer Center. Abgerufen am 10. Februar 2022.
Jim Stallard: FDA Grants Breakthrough Therapy Designation to Naxitamab for Neuroblastoma | Memorial Sloan Kettering Cancer Center. Abgerufen am 10. Februar 2022.

nih.gov

ncbi.nlm.nih.gov

Nai-Kong V. Cheung, H. Guo, Jian Hu, D. V. Tassev, I. Y. Cheung: Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. In: OncoImmunology. Band 1, Nr. 4, 2012, S. 477–486, doi:10.4161/onci.19864, PMID 22754766.
Ketan Patel, R. J. Rossell, L. F. Pemberton, N. K. Cheung, F. S. Walsh, S. E. Moore, T. Sugimoto, J. T. Kemshead: Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2. In: British Journal of Cancer. Band 60, Nr. 6, 1989, S. 861–866, doi:10.1038/bjc.1989.380, PMID 2481486.
Jeong A. Park, Nai-Kong V. Cheung: Targets and Antibody Formats for Immunotherapy of Neuroblastoma. In: Journal of Clinical Oncology. Band 38, Nr. 16, 2020, S. 1836–1848, doi:10.1200/jco.19.01410, PMID 32167865.

seekingalpha.com

Y-mAbs: Efficacy Data Concerns, Poor Management History, And Insider Sales (NASDAQ:YMAB) | Seeking Alpha. Abgerufen am 10. Februar 2022.

who.int

INN Recommended List 82, World Health Organisation (WHO), 9. September 2019.

ymabs.com

ir.ymabs.com

SIOP 2019 Naxitamab-Based Chemoimmunotherapy for Resistant High-Risk Neuroblastoma – Interim Results of HITS. Abgerufen am 10. Februar 2022.